EICHORCondition: Advanced Solid Tumors · Sponsor: Regeneron Pharmaceuticals
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by itself and in combination with cemiplimab (with or without chemotherapy), and to find out what is the best dose of marlotamig to be given to patients with advanced solid tumors when combined with cemiplimab (with or without chemotherapy). Another aim of the study is to see how effective marlotamig by itself, or in combination with cemiplimab (with or without chemotherapy), is at treating cancer patients. The study is also looking at: * Side effects that may be experienced by people taking marlotamig by itself and in combination with cemiplimab with or without chemotherapy * How marlotamig works in the body by itself and in combination with cemiplimab with or without chemotherapy * How much marlotamig is present in the blood when given by itself and in combination with cemiplimab with or without chemotherapy * To see if marlotamig by itself and in combination with cemiplimab with or without chemotherapy works to treat cancer by controlling the proliferation of tumor cells to shrink the tumor * Whether the body makes antibodies against the study drugs (marlotamig and cemiplimab) (which could make the drug less effective or could lead to side effects)
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Valkyrie Clinical Trials | Los Angeles, California, United States | — |
| University of California Los Angeles (UCLA) Medical Center | Los Angeles, California, United States | — |
| The Regents of the University of California, San Francisco | San Francisco, California, United States | — |
| University of Colorado Hospital - Anschutz Cancer Pavilion - Lung Cancer Clinic | Aurora, Colorado, United States | — |
| University of Florida Health | Gainesville, Florida, United States | — |
| Moffitt Cancer Center | Tampa, Florida, United States | — |
| University of Illinois Cancer Center | Chicago, Illinois, United States | — |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | — |
| START Midwest - Cancer & Hematology Centers of Western Michigan, PC | Grand Rapids, Michigan, United States | — |
| Rutgers Cancer Institute of New Jersey | New Brunswick, New Jersey, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| University of Cincinnati Medical Center | Cincinnati, Ohio, United States | — |
+ 42 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04626635